Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	2	31,632	N/A	N/A	73.27% (35.82% to 88.87%)
Confirmed symptomatic COVID‐19 after complete vaccination	2	31,632	N/A	N/A	93.20% (91.06% to 94.83%)
Severe or critical COVID‐19 after complete vaccination	1	28,451	N/A	N/A	98.20% (92.80% to 99.60%)
All‐cause mortality	1	30,346	Risk Ratio (M‐H, Random, 95% CI)	1.06 (0.54 to 2.10)	N/A
Serious adverse events	2	34,072	Risk Ratio (M‐H, Random, 95% CI)	0.92 (0.78 to 1.08)	N/A
Systemic reactogenicity events	2	34,037	Risk Ratio (M‐H, Random, 95% CI)	1.28 (1.22 to 1.34)	N/A
Any adverse event	2	34,072	N/A	Outcome not pooled due to considerable heterogeneity	N/A
Local reactogenicity events	2	34,037	Risk Ratio (M‐H, Random, 95% CI)	3.30 (2.02 to 5.40)	N/A
CI: confidence interval; N/A: not applicable.